Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
Journal
ESMO open
Journal Volume
7
Journal Issue
5
Date Issued
2022-10
Author(s)
Simonelli, M
Garralda, E
Eskens, F
Gil-Martin, M
Yen, C-J
Obermannova, R
Chao, Y
Lonardi, S
Melichar, B
Moreno, V
Yu, M-L
Bongiovanni, A
Calvo, E
Rottey, S
Machiels, J-P
Gonzalez-Martin, A
Paz-Ares, L
Chang, C-L
Mason, W
Reardon, D A
Vieito, M
Santoro, A
Meng, R
Abbadessa, G
Menas, F
Lee, H
Liu, Q
Combeau, C
Ternes, N
Ziti-Ljajic, S
Massard, C
Abstract
The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there are no data on its efficacy in solid tumors. This phase I/II study (NCT03637764) assessed the safety and activity of isatuximab plus atezolizumab (Isa + Atezo), an anti-programmed death-ligand 1 (PD-L1) antibody, in patients with immunotherapy-naive solid tumors: epithelial ovarian cancer (EOC), glioblastoma (GBM), hepatocellular carcinoma (HCC), and squamous cell carcinoma of the head and neck (SCCHN).
Subjects
anti-CD38; anti-PD-L1; atezolizumab; isatuximab; solid tumors
SDGs
Type
journal article